Warning issued about ads for fake weight-loss drug Ozempic that pose serious ‘health risk'
'We know that a lot of people are being duped into purchasing fake and illegal products via these sites'
Ireland's medicines watchdog has issued an urgent warning about ads for fake weight-loss drugs that pose 'a health risk' to the public.
The Health Products Regulatory Authority (HPRA) said it has identified a 'surge' in online advertisements making 'spurious claims and featuring false endorsements'.
The advertisements often offer fake versions of drugs such as semaglutide and tirzepatide – the active ingredients in weight-loss jabs such as Ozempic and Mounjaro.
The HPRA said it had identified a significant increase in recent weeks of online content making false claims while promoting medicines, medical devices and cosmetics.
However, the Authority is specifically highlighting a new development 'where dubious sites and social media posts are using the HPRA logo to falsely claim featured products are endorsed' by the body.
'Other regulatory bodies internationally are being targeted in a similar way,' a HPRA statement reads.
'The unacceptable use of the HPRA logo and name in this way is clearly designed to deceive and mislead consumers.'
A genuine package of the Novo Nordisk weight loss drug Ozempic.
News in 90 Seconds - May 31st
As a result, the authority is urging members of the public not to buy such products online 'as they are likely to be from untrustworthy suppliers both engaged in illegal advertising and offering fake or unauthorised products that could pose a health risk'.
'As the independent regulator, the HPRA will never endorse or promote any specific health product or brand,' the statement adds.
According to the HPRA, they have observed a 'surge' in misleading website activity in May alone.
Hundreds of Facebook profiles and 414 Facebook advertisements have been identified making false claims 'with many also fraudulently stating that the product or brand is endorsed by the HPRA'.
The HPRA said it had alerted various platforms 'of this fraudulent activity and of the public health risks associated with illegal prescription medicines and other unregulated health products sold online'.
Grainne Power, Director of Compliance, HPRA, said that despite what is being claimed in recent posts, 'these illegal products are manufactured and sourced outside of Ireland'.
'We know that a lot of people are being duped into purchasing fake and illegal products via these sites,' Ms Power said.
'Working with Revenue's Customs Service, we have detained a significant number of products at point of entry to the country. A number of these purport to be genuine prescription medicines when in fact the products as presented do not exist as an authorised product in any market.'
Ms Power stressed that the key message is that the HPRA never endorses individual brands, 'nor do we allow our logo to be used in the promotion of health products'.
'Our advice to consumers is that if online sources feature a HPRA logo or suggest a HPRA endorsement, then this is actually a clear sign you are engaging with a dubious site and seller,' she added.
'At best you are wasting your money with these online scams but at worst you could be seriously endangering your health. We are advising that when it comes to prescription medicines, ensure that the product is prescribed by a healthcare professional and sourced from a local pharmacy.
'All medicines, medical devices and cosmetics should be purchased through trustworthy, reliable and recognised sources.'
In July of last year, a warning was issued to the public as fake Ozempic syringe seizures trebled in Ireland.
The Health Products Regulatory Authority (HPRA) revealed that 656 units of fake Ozempic were seized in Ireland within the first five months of 2024.
Only 254 units were seized in Ireland for all of the previous twelve months.
The Irish public has been warned not to purchase Ozempic from unknown sources, especially online.
Trinity Professor Luke O'Neill said fake Ozempic could be 'lethal' as people 'don't know' what they are purchasing.
'These are people making, not snake oil, but kind of a tube that hasn't got Ozempic in it, it's got something else and they are calling it Ozempic,' he told Newstalk.
'You don't know what you're getting.'
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
The Irish Sun
an hour ago
- The Irish Sun
I recovered from booze & drug addiction then piled on 3 stone – Mounjaro was the only thing that helped
CAT Sims has opened up about turning to Mounjaro after quitting booze and drugs lead her turning to food and piling on three stones. Author and podcaster Cat, 43, from London , hailed the weight loss jab as 'rehab for food' and praised it for being a 'silver bullet.' Advertisement 8 Cat Sims has opened up about using Mounjaro after battling with 'food addiction' Credit: Instagram 8 Cat with her husband Jimmy and their two daughter Billie and Bo Credit: Supplied Cat has previously opened up about However, she then struggled with food. Speaking on the podcast, Made by Mammas, she candidly shared that she is 'all or nothing' and food is a 'big issue for her.' Cat, who is married to husband Jimmy and has two daughters, Billie and Bo, explained: 'I think actually that was probably my first addiction. Advertisement More on Mounjaro 'But for me, I'm sure there are people who can balance who can moderate. I do not have that gene. 'I've recently started Mounjaro, I've recently started the weight loss jabs. 'I was three stone heavier than I was when I gave up booze. 'I think people think if you give up booze you're going to lose a little weight. Advertisement Most read in Fabulous 'I lost nothing. I just went straight into food and chocolate and sugar.' She then explained how Mounjaro has helped her 'food addiction', and said: 'For me it's like rehab for food addiction. I was depressed and exhausted before Mounjaro - I've lost 4 stone but have had FOUL side effects, including eggy burps 'You're locked down and while you're there you do all the work, so that when you come out of rehab you can do it on your own. 'And that's what Mounjaro is for me.' Advertisement Cat shared how she feels like her food addiction is now gone thanks to the 8 Cat Sims opened up on Made by Mammas: The Podcast Credit: Cat Sims - Made by Mammas: The Podcast 8 Cat Sims has bravely spoken out about battling her booze addiction Credit: Tash Busta 8 The mum-of-two has been sober since 26 November 2021 Credit: Supplied Advertisement She added: 'I have no cravings for the crappy food or the ultra processed stuff. 'It was always a difficult thing because with booze and alcohol I was always like I can just abstain, I don't have to have those things, but food, I can't just not eat. 'But now I think doing the work I'm doing while I'm on the injections has made me realise that I can abstain from the ultra processed stuff. 'There are side effects, as there are with any drug or medication or anything that you put into you that isn't naturally supposed to be, but for me, it's been a silver bullet in terms of helping me manage what is essentially a food addiction, you know, and also I'm perimenopausal.' Advertisement 8 Cat found that she had a 'habit of drinking to blackout' Credit: Supplied 8 Cat thought she was 'living for the moment' by heading out for drinks Credit: Supplied 8 Cat is now living a calm and peaceful sober life Credit: Supplied MOUNJARO TAKEOVER Mounjaro injections are licensed for patients with Advertisement They are also available to assist those who are clinically obese (with a The drugs, which have been widely regarded as 'fat jabs', can be prescribed by a practitioner - such as a doctor, nurse or a pharmacist-independent prescriber. But increasingly, we are seeing more and more people buying them through online pharmacies, without sufficient checks. Not only this, but recently, figures from the Medicines and Healthcare products Regulatory Agency revealed that Advertisement Everything you need to know about fat jabs Weight loss jabs are all the rage as studies and patient stories reveal they help people shed flab at almost unbelievable rates, as well as appearing to reduce the risk of serious diseases. Wegovy – a modified version of type 2 diabetes drug Ozempic – and Mounjaro are the leading weight loss injections used in the UK. Wegovy, real name semaglutide, has been used on the NHS for years while Mounjaro (tirzepatide) is a newer and more powerful addition to the market. Mounjaro accounts for most private prescriptions for weight loss and is set to join Wegovy as an NHS staple this year. How do they work? The jabs work by suppressing your appetite, making you eat less so your body burns fat for energy instead and you lose weight. They do this my mimicking a hormone called GLP-1, which signals to the brain when the stomach is full, so the drugs are officially called GLP-1 receptor agonists. They slow down digestion and increase insulin production, lowering blood sugar, which is why they were first developed to treat type 2 diabetes in which patients' sugar levels are too high. Can I get them? NHS prescriptions of weight loss drugs, mainly Wegovy and an older version called Saxenda (chemical name liraglutide), are controlled through specialist weight loss clinics. Typically a patient will have to have a body mass index (BMI) of 30 or higher, classifying them as medically obese, and also have a weight-related health condition such as high blood pressure. GPs generally do not prescribe the drugs for weight loss. Private prescribers offer the jabs, most commonly Mounjaro, to anyone who is obese (BMI of 30+) or overweight (BMI 25-30) with a weight-related health risk. Private pharmacies have been rapped for handing them out too easily and video calls or face-to-face appointments are now mandatory to check a patient is being truthful about their size and health. Are there any risks? Yes – side effects are common but most are relatively mild. Around half of people taking the drug experience gut issues, including sickness, bloating, acid reflux, constipation and diarrhoea. Dr Sarah Jarvis, GP and clinical consultant at said: 'One of the more uncommon side effects is severe acute pancreatitis, which is extremely painful and happens to one in 500 people.' Other uncommon side effects include altered taste, kidney problems, allergic reactions, gallbladder problems and hypoglycemia. Evidence has so far been inconclusive about whether the injections are damaging to patients' mental health. Figures obtained by The Sun show that, up to January 2025, 85 patient deaths in the UK were suspected to be linked to the medicines.
The Irish Sun
4 hours ago
- The Irish Sun
Woman dies after ‘medical episode' at gym as she is ‘pulled from swimming pool'
A WOMAN has died after a "medical episode" at the gym as paramedics "pulled her from the swimming pool". Emergency services were called to Total Fitness, in Preston, at around 5.30pm on Monday. Advertisement Lancashire Constabulary said the woman, believed to be in her 60s, had "been pulled from the swimming pool" after a suspected medical episode. Despite the best efforts of paramedics, she tragically died at the scene. The gym was closed last night while investigations continue. Cops said the woman's death is not being treated as suspicious. Advertisement Read More A force spokesperson told "A woman, believed to be in her 60s, had been pulled from the swimming pool following a suspected medical episode. "Despite the best efforts of staff and medical teams the woman sadly died at the scene. "Our thoughts are with her loved ones at this time. The death is not being treated as suspicious, and a file will be passed to HM Coroner in due course." Advertisement Most read in The Sun North West Ambulance Service has been contacted for comment. 1 A woman died after a "medical episode" at a Preston gym Credit: Google Maps More to follow... For the latest news on this story keep checking back at The Sun Online is your go-to destination for the best celebrity news, real-life stories, jaw-dropping pictures and must-see video. Advertisement Like us on Facebook at
RTÉ News
9 hours ago
- RTÉ News
'Hope on horizon' as new drugs tested for Alzheimer's treatment
Dementia experts have said that "hope is on the horizon" after a new review shows a rise in the number of potential drugs that could treat or prevent Alzheimer's disease. Some 138 new treatments are being assessed for the treatment and prevention of Alzheimer's. A third of drugs currently being trialled are "repurposed" medications that are already being used to tackle other diseases, including diabetes, multiple sclerosis and cholesterol, according to the new review. One such trial is assessing whether semaglutide, the main ingredient for the weight loss and diabetes drug Ozempic and weight loss drug Wegovy, can slow the progression of dementia. And four late-stage trials are looking at preventing disease. Experts said that drugs targeting amyloid protein build up in the brain, such as lecanemab and donanemab, are "only one part of the overall strategy" as they expressed excitement over the variety of new drugs, which are being tested among patients. The new review of Alzheimer's disease in clinical trials in 2025 found 182 clinical trials assessing the impact of 138 drugs. The number of trials represents an 11% increase on the previous year, according to the review, which was led by an expert from the University of Nevada in the US and has been published in the journal Alzheimer's and Dementia: Translational Research and Clinical Interventions. Commenting on the paper, Dr Sheona Scales, director of research at Alzheimer's Research UK, said: "This year has really given us real cause for optimism." She said that as well as more drugs coming through the pipeline, the treatment targets are "more diverse" and "looking at all stages of the disease". She added: "What this paper is showing us is that the pipeline of drug development is growing, it's diversifying and accelerating." "This latest report shows us that there is hope on the horizon for people with Alzheimer's, building on lecanemab and donanemab." Dr Emma Mead, chief scientific officer of the Oxford Drug Discovery Institute, added: "Today we are at a tipping point in dementia research as we understand more and more about the diseases that drive dementia. "This gives us opportunities to slow and ultimately stop this devastating condition and today's announcement demonstrates that researchers are able to translate these understandings towards potential new treatments." James Rowe, professor of cognitive neurology at the University of Cambridge and consultant neurologist, said: "What strikes me is not just the number of new drugs, which is increasing year on year, but their range of targets (and) the range in which they work, giving us multiple shots on goal." On the drugs which are being investigated for the prevention of disease, Prof Rowe said: "One of the most exciting things of this report is the number of large-scale late-stage trials on prevention. "And the aspiration to prevent, not just treat, is starting to be seen in the figures we see in these charts today." He added: "One way this can work is you take a treatment that you show to be working in people with symptoms with the illness, and then you simply bring it forward by some years. "The ones that are in trial at the moment are really... bringing forward an effective treatment to earlier stage." For instance, people with a genetic risk of Alzheimer's could receive some drugs earlier to see if they protect against the disease. On the repurposing of current drugs, Dr Mead said that it can usually take ten to 15 years for new drugs to be tested and approved for use. "Being able to repurpose drugs licensed for other health conditions could help to accelerate progress and help to open up other avenues to prevent or treat dementia causing diseases," she said. "A really promising example of this is the drug semaglutide, which is currently being trialled in people with mild cognitive impairment." Meanwhile, academics said lecanemab and donanemab, which can be used for treating mild cognitive impairment in Alzheimer's patients, are an "important first step" in the battle against the disease. The treatments were initially approved for UK use by regulators but then deemed not cost-effective for NHS use. The National Institute for Health and Care Excellence (NICE) is taking more evidence on donanemab and lecanemab and is expected to announce its decision in the summer. Dr Scales added: "Lecanemab and donanemab have represented a huge leap forward in our understanding and ability to be able to treat Alzheimer's disease. "What they've done is they've proved that we're able to modify the course of Alzheimer's disease, and what that has done is opened up the door to future treatments that we hope are more effective, easier to deliver and able to deliver for our patients." She said studies are showing "even more complexities" around Alzheimer's and that in the future, people may be treated with a combination of drugs, depending on when they are diagnosed and the type of dementia they have.
